Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma

Araújo, Anelise Bergmann; Soares, Tahiane; Schmalfuss, Tissiana; Angeli, Melissa Helena; Furlan, Juliana Monteiro; Salton, Gabrielle Dias; Burin, Mariana Monteiro; Röhsig, Liane Marise

doi:10.1111/trf.17090

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our ASCT cases took longer in neutrophil recovery than those reported in previous studies [7, 9, 12, 13, 20, 21]. One possible reason is that our study concerned only patients with haematological malignancies but without solid tumors and autoimmune disorders.…”

Section: Discussionmentioning

confidence: 75%

A critical assessment of dose effects of post‐thaw CD34 on autologous stem cell transplantation treatment of haematological malignancies

Duarte¹,

Butler

Atkinson³

et al. 2023

eJHaem

View full text Add to dashboard Cite

A consensus threshold of pre‐cryopreservation CD34‐positive cells (CD34s) has been used as the minimum dose to initiate autologous stem cell transplantation (ASCT). Advances in cryopreservation posed a debate whether post‐thaw CD34s might be a superior surrogate instead. We addressed the debate in this retrospective study of 217 adult ASCTs in five different haematological malignancies treated at a single centre. We showed that post‐thaw CD34s was highly correlated with pre‐cryopreservation CD34s (r = 0.97) and explained ∼2.2% (p = 0.003) of the variation of the post‐thaw total nucleated cell viability that however had no power to predict engraftment outcomes. After stratifying the ASCT cases into four dose groups based on post‐thaw CD34s reinfused, stepwise multivariate regression analyses detected significant effects in dose group and interactions with diseases for neutrophil and platelet recovery respectively. The significant dose effects and interactions were triggered by two technical outliers in the low dose group, and disappeared in the repeated regressions after exclusion of the outliers where disease and age were the significant predictors remained. Our data clearly support the validity of the consensus threshold in ASCT applications but also highlight neglected conditions where monitoring post‐thaw CD34s and clinical attributes are valuable.

show abstract

Section: Discussionmentioning

confidence: 75%

A critical assessment of dose effects of post‐thaw CD34 on autologous stem cell transplantation treatment of haematological malignancies

Duarte¹,

Butler

Atkinson³

et al. 2023

eJHaem

View full text Add to dashboard Cite

show abstract

“…Several studies highlight the benefits of using fresh autologous stem cell products over cryopreserved ones for transplantation. For example, fresh products show faster engraftment with a lower incidence of neutropenia than cryopreserved products [18][19][20]. Furthermore, cryopreservation causes physiological changes in stem cell products, including cell aggregation [19].…”

Section: Discussionmentioning

confidence: 99%

“…For example, fresh products show faster engraftment with a lower incidence of neutropenia than cryopreserved products [18][19][20]. Furthermore, cryopreservation causes physiological changes in stem cell products, including cell aggregation [19]. In the majority of studies, the duration of fresh hypothermal storage is 48-72 hours for myeloma and lymphoma patients, indicating the potential benefits of extending the shelf life of fresh PBHSCs products [20].…”

Section: Discussionmentioning

confidence: 99%

Validation of long-term handling and storage conditions for hematopoietic stem cell products for autologous transplants

Owaidah,

Mohanna,

Albahrani

et al. 2023

JMedLife

View full text Add to dashboard Cite

Hematopoietic stem cells (HPSCs) are multipotent stem cells that can differentiate into lymphoid and myeloid progenitors, giving rise to white blood cells (WBCs), red blood cells (RBCs), and platelets. HPSCs are a widely used treatment for many hematological non-malignant and malignant disorders. HPSCs can be used in the fresh or cryopreserved state for future use. Fresh HPSCs are typically stored at 2-6°C for up to 72 hours and are primarily used for allogeneic transplants or autologous transplants in myeloma and lymphoma patients. However, in some cases of autologous donations, HPSC transplantation is delayed more than three days after collection. In such situations, the cells are thawed after short-term preservation, resulting in a 35% cell viability loss. This study aimed to investigate the quality of HPSCs products after long-term storage exceeding 72 hours. The quality of HPSCs products was assessed by measuring viable CD34+ cell count, the total number of nucleated cells (TNC), and HPSCs recovery after different storage intervals of up to 120 hours in hypothermal storage. The mean total cell viability decreased by 2.18% within 72 hours and 7.4% within 120 hours, while mean CD34+ cell recovery was 92.61 % at 72 hours and 83.83 % at 120 hours in hypothermal storage. The mean TNC recovery was 89.93% at 72 hours and 76.18 % at 120 hours. All products were free from bacterial contamination for up to 120 hours under hypothermal storage conditions.

show abstract

“…Bone marrow (BM) is an alternate source of hepatocytes in the context of liver damage [ 148 – 151 ]. Previous research has shown that BM can generate a range of adult stem cells that express biomarkers for non-haematopoietic progenitor cells [ 152 – 154 ]. Although they may produce hepatocytes under tissue stress, BM cells have little impact on parenchymal replenishment in liver damage [ 27 , 155 – 158 ].…”

Section: Diverse Cell Sources and Therapeutic Sites For Cell Therapymentioning

confidence: 99%

Cell therapy in end-stage liver disease: replace and remodel

Chen

Wu³

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

Liver disease is prevalent worldwide. When it reaches the end stage, mortality rises to 50% or more. Although liver transplantation has emerged as the most efficient treatment for end-stage liver disease, its application has been limited by the scarcity of donor livers. The lack of acceptable donor organs implies that patients are at high risk while waiting for suitable livers. In this scenario, cell therapy has emerged as a promising treatment approach. Most of the time, transplanted cells can replace host hepatocytes and remodel the hepatic microenvironment. For instance, hepatocytes derived from donor livers or stem cells colonize and proliferate in the liver, can replace host hepatocytes, and restore liver function. Other cellular therapy candidates, such as macrophages and mesenchymal stem cells, can remodel the hepatic microenvironment, thereby repairing the damaged liver. In recent years, cell therapy has transitioned from animal research to early human studies. In this review, we will discuss cell therapy in end-stage liver disease treatment, especially focusing on various cell types utilized for cell transplantation, and elucidate the processes involved. Furthermore, we will also summarize the practical obstacles of cell therapy and offer potential solutions.

show abstract

Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma

Cited by 5 publications

References 22 publications

A critical assessment of dose effects of post‐thaw CD34 on autologous stem cell transplantation treatment of haematological malignancies

A critical assessment of dose effects of post‐thaw CD34 on autologous stem cell transplantation treatment of haematological malignancies

Validation of long-term handling and storage conditions for hematopoietic stem cell products for autologous transplants

Cell therapy in end-stage liver disease: replace and remodel

Contact Info

Product

Resources

About